Protara Therapeutics, Inc. — Director's Dealing 2019

Jan 23, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: PROTEON THERAPEUTICS INC (PRTO)
CIK: 0001359931
Period of Report: 2019-01-18

Reporting Person: Burke Steven Keith (SVP and Chief Medical Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-01-18	Stock Option (Right to Buy)	$2.64	A	145000	Acquired	2029-01-17	Common Stock, $0.001 par value (145000)	Direct

Footnotes

F1: The options were granted on January 18, 2019 and the shares underlying this option vest 25% on the first anniversary of the grant date and the remaining shares vest in twelve equal quarterly installments.